

NDA 209606/S-004

SUPPLEMENT APPROVAL

Celgene Corporation Attention: Qing Wu, MS Senior Manager, Regulatory Affairs 86 Morris Avenue Summit, NJ 07901

Dear Ms. Wu:

Please refer to your supplemental new drug application (sNDA) dated June 29, 2020, received June 29, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for IDHIFA (enasidenib) tablets.

This Prior Approval supplemental new drug application provides for the following:

- Revisions to Sections 7.1 Effect of IDHIFA on Other Drugs and 12.3
 Pharmacokinetics of the United States Prescribing Information (USPI) to include specific information on substrates and transporter systems;
- Revisions to Section 17 Patient Counseling Information of the USPI to include the *Drug Interactions* subsection;
- Minor editorial edits in Sections 5.2 Embryo-Fetal Toxicity, 8.1 Pregnancy, 8.2 Lactation, 8.3 Females and Males of Reproductive Potential and 17 Patient Counseling Information of the USPI;
- Revisions to the Medication Guide to reflect changes in Section 17 of the USPI.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(I)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at



FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (Prescribing Information and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELING

We acknowledge your October 13, 2020, submission containing final printed carton and container labeling.

REQUIRED PEDIATRIC ASSESSMENTS


Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-*

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.





¹ http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

NDA 209606/S-004 Page 3

Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Saumya Nathan, Regulatory Project Manager, at 301-348-1963.

Sincerely,

{See appended electronic signature page}

Brian Booth, PhD
Division Director
Division of Cancer Pharmacology I
Office of Clinical Pharmacology
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - o Prescribing Information
 - o Medication Guide

⁵ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf





³ For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.

⁴ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

.....

/s/

BRIAN P BOOTH 11/24/2020 10:20:24 AM

